Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	3.65
Equity-to-Asset	0.72
Debt-to-Equity	0.07
Debt-to-EBITDA	0.23
Interest Coverage	44.22
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	8.68	Distress Grey Safe
Beneish M-Score	-2.34	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	12
	3-Year EBITDA Growth Rate	33.1
	3-Year EPS without NRI Growth Rate	13.5
	3-Year FCF Growth Rate	19
	3-Year Book Growth Rate	14.1
	Future 3-5Y EPS without NRI Growth Rate	4.14
	Future 3-5Y Total Revenue Growth Rate	7.34

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	75.76
	9-Day RSI	64.01
	14-Day RSI	57.97
	6-1 Month Momentum %	12.95
	12-1 Month Momentum %	26.48

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.55
	Quick Ratio	1.9
	Cash Ratio	0.77
	Days Inventory	172.72
	Days Sales Outstanding	100.3
	Days Payable	85.89

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.64
	Dividend Payout Ratio	0.13
	3-Year Dividend Growth Rate	14.5
	Forward Dividend Yield %	0.64
	5-Year Yield-on-Cost %	0.97
	3-Year Average Share Buyback Ratio	-0.1
	Shareholder Yield %	1.4

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	58.28
	Operating Margin %	23.99
	Net Margin %	19.24
	FCF Margin %	10.58
	ROE %	21.44
	ROA %	15.48
	ROIC %	21.95
	ROC (Joel Greenblatt) %	52.29
	ROCE %	28.07
	Years of Profitability over Past 10-Year	10

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	19.84
	Forward PE Ratio	20.37
	PE Ratio without NRI	20.81
	Shiller PE Ratio	35.37
	Price-to-Owner-Earnings	17.55
	PEG Ratio	1.1
	PS Ratio	3.82
	PB Ratio	3.86
	Price-to-Tangible-Book	4.59
	Price-to-Free-Cash-Flow	36.1
	Price-to-Operating-Cash-Flow	19.33
	EV-to-EBIT	14.01
	EV-to-Forward-EBIT	13.86
	EV-to-EBITDA	11.65
	EV-to-Forward-EBITDA	11.64
	EV-to-Revenue	3.64
	EV-to-Forward-Revenue	3.29
	EV-to-FCF	34.25
	Price-to-Projected-FCF	2.16
	Price-to-Median-PS-Value	1.12
	Price-to-Peter-Lynch-Fair-Value	0.9
	Price-to-Graham-Number	2.07
	Price-to-Net-Current-Asset-Value	7.8
	Earnings Yield (Greenblatt) %	7.14
	FCF Yield %	2.75
	Forward Rate of Return (Yacktman) %	22.35

GF Value: ₹5897.47

BOM:500124

Warning Signs

Warning! GuruFocus detected 2 Medium warning signs with 500124. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.